Back to search results

Understanding Heart Failure: A Precision Medicine Registry

This study aims to better understand different types of heart failure and how they progress. Researchers will collect information like blood samples (including DNA), medical history, and imaging data from people with and without heart failure. The goal is to find better ways to match the right treatments to the right patients, which is called precision medicine. You may be able to join if you are 18 or older and have heart failure symptoms, along with specific blood test results (NT-proBNP over 125 pg/mL or BNP over 35 pg/mL) or heart catheterization findings. The main thing they will be looking for is major adverse cardiovascular events (like heart attacks or strokes) up to 60 months after the study ends.

Study design
This is an observational study, meaning no specific interventions are being tested. It plans to include up to 3000 participants.
What's involved
Participants will provide baseline and one-year follow-up blood samples, including DNA. Clinical characteristics, medical history, and imaging data will also be collected.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for major adverse cardiovascular events for up to 60 months after the study closure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03480633

Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure

Recruiting
Not specifiedAges 18+Observational
Massachusetts General Hospital
~3,000 participants
Updated 2025-12-09 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Major adverse cardiovascular events (MACE)
Measured over Time from sample collection until the date of documented event up to 60 months after the study closure.

Conditions

Heart Failure With Normal Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Heart Failure, Right Sided
Heart Failure With Mid Range Ejection Fraction
Cardiovascular Risk Factor

Explore related trials

Heart Disease Risk FactorsHeart FailureHeart failure with mid range ejection fractionHeart failure with normal ejection fractionHeart failure with reduced ejection fractionRight Heart FailureNPPB wt AlleleN-Terminal Fragment Brain Natriuretic Protein

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Hanna Gaggin, MD, MPH · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Abbie Macher, BS
[email protected]
617-643-6328
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years and older
History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF:
NT-proBNP \> 125 pg/mL
BNP \> 35 pg/mL
Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI \<2.8 L/min/m2
LVEDP ≥ 15 mmHg
Radiographic evidence of pulmonary edema
Improvement in symptoms with diuretic initiation of increase
CPET evidence of cardiac etiology of symptoms

What this trial measures

  • Major adverse cardiovascular events (MACE)Time from sample collection until the date of documented event up to 60 months after the study closure.

    MACE as defined by a combined end point of all-cause mortality and HF hospitalizations.